DE60323489D1 - Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten - Google Patents

Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten

Info

Publication number
DE60323489D1
DE60323489D1 DE60323489T DE60323489T DE60323489D1 DE 60323489 D1 DE60323489 D1 DE 60323489D1 DE 60323489 T DE60323489 T DE 60323489T DE 60323489 T DE60323489 T DE 60323489T DE 60323489 D1 DE60323489 D1 DE 60323489D1
Authority
DE
Germany
Prior art keywords
cox
preparations
prevention
treatment
mediated diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60323489T
Other languages
English (en)
Inventor
Lionel Bovetto
Joerg Hau
Catherine Mace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60323489(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Application granted granted Critical
Publication of DE60323489D1 publication Critical patent/DE60323489D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
DE60323489T 2003-09-12 2003-09-12 Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten Expired - Lifetime DE60323489D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03020739.3A EP1514482B2 (de) 2003-09-12 2003-09-12 Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten

Publications (1)

Publication Number Publication Date
DE60323489D1 true DE60323489D1 (de) 2008-10-23

Family

ID=34130196

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60323489T Expired - Lifetime DE60323489D1 (de) 2003-09-12 2003-09-12 Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten

Country Status (16)

Country Link
US (1) US8012509B2 (de)
EP (2) EP1514482B2 (de)
JP (1) JP4824560B2 (de)
CN (1) CN1849076B (de)
AR (1) AR045745A1 (de)
AT (1) ATE407574T2 (de)
AU (1) AU2004271722B2 (de)
BR (1) BRPI0413714A (de)
CA (1) CA2537544C (de)
CR (1) CR8265A (de)
DE (1) DE60323489D1 (de)
ES (1) ES2314152T3 (de)
MX (1) MXPA06002648A (de)
PT (1) PT1514482E (de)
TW (1) TW200524545A (de)
WO (1) WO2005025335A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006313660B2 (en) * 2005-11-14 2012-07-19 Nestec S.A. Oral tolerance promotion with glycated proteins
NL1033698C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
US20080293159A1 (en) * 2007-05-24 2008-11-27 Murray Goulburn Co-Operative Co. Ltd. Validation Process
US9066526B2 (en) * 2009-10-16 2015-06-30 Dairy Australia Limited Allergy treatment using acid treated aqueous whey protein extract
WO2012050895A1 (en) * 2010-09-28 2012-04-19 Lisa Geng Methods for treating neurological disorders using nutrient compositions
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
CN105613731B (zh) * 2016-03-17 2019-12-31 广西壮族自治区水牛研究所 一种发酵乳制品
DE112019002696A5 (de) * 2018-05-30 2021-02-18 DÖHLER GmbH Hochdruckverfahren, insbesondere zur Haltbarmachung von Lebensmitteln, Pharmazeutika und Kosmetika sowie Hochdruckvorrichtung
WO2020159357A1 (en) * 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748847A1 (de) * 1976-11-05 1978-05-11 Stauffer Chemical Co Verfahren zum verstaerken saurer alkoholfreier getraenke mit protein und verstaerkungsmittel auf proteinbasis
US4358464A (en) * 1977-08-02 1982-11-09 Superior Dairy, Inc. Process for converting sour whey into sweet whey and product
US4284623A (en) * 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
DE3141914A1 (de) * 1981-10-22 1983-05-05 Babcock-BSH AG vormals Büttner-Schilde-Haas AG, 4150 Krefeld Verfahren zur herstellung von frischkaese
JPS6339545A (ja) * 1986-08-04 1988-02-20 Meiji Milk Prod Co Ltd 牛乳ホエ−中のβ−ラクトグロブリンの除去方法
JP2622686B2 (ja) * 1987-05-15 1997-06-18 雪印乳業株式会社 ｋ−カゼイングリコマクロペプチドの製造法
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
US5888552A (en) 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DE4413839C1 (de) 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
DE19649891C2 (de) * 1996-12-02 1998-12-10 Mk Produktkontor Gmbh Verwendung von antioxidativen Zusammensetzungen mit Süßmolkekonzentrat
DE19726868A1 (de) * 1997-06-24 1999-01-07 Mk Produktkontor Gmbh Antioxidative Zusammensetzungen mit Süßmolkekonzentrat
EP1094824B1 (de) * 1998-06-10 2006-04-05 Albert B. Crum Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
US6558716B1 (en) * 1999-01-14 2003-05-06 Kraft Foods Holdings, Inc. Process for incorporating whey protein into cheese
DE19918219C1 (de) * 1999-04-22 2001-01-18 Dornier Gmbh Lebensdauer-Indikator für hochbeanspruchte Leichtbau-Strukturen
DE19918210A1 (de) 1999-04-22 2000-11-02 Biomun Gmbh Verfahren zur Herstellung eines Milchpräparates mit verzögerter Inhaltsstoff-Freisetzung und seine Verwendung
US6777391B1 (en) * 1999-04-29 2004-08-17 Nestec S.A. Composition for an infant formula having a low threonine content
US6469063B1 (en) * 1999-11-18 2002-10-22 City Of Hope Inhibition of inflammation via inhibition of COX-2 gene transcription
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
FR2808444B1 (fr) 2000-05-05 2004-03-26 Francois Ballestra Utilisation d'une fraction du lait d'equide pour la fabrication d'une composition possedant une activite d'inhibition de la production de l'interleukine-1 et composition ainsi obtenue
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
WO2002051437A1 (en) * 2000-12-22 2002-07-04 Societe Des Produits Nestle S.A. Induction of tolerance
US20020169195A1 (en) * 2001-01-26 2002-11-14 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
US6589574B2 (en) * 2001-03-19 2003-07-08 Council Of Scientific & Industrial Research Process for preparation of protein-hydrolysate from milk protein
US20030026845A1 (en) * 2001-06-18 2003-02-06 Etzel Lisa R. Process for preparing protein isolate from milk, whey, colostrum, and the like
FR2827290B1 (fr) * 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
DE10208034A1 (de) 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt

Also Published As

Publication number Publication date
EP1955602A1 (de) 2008-08-13
ATE407574T2 (de) 2008-09-15
JP4824560B2 (ja) 2011-11-30
CN1849076B (zh) 2010-06-09
CA2537544A1 (en) 2005-03-24
CA2537544C (en) 2012-12-11
CR8265A (es) 2006-07-14
BRPI0413714A (pt) 2006-10-17
US20070110818A1 (en) 2007-05-17
ES2314152T3 (es) 2009-03-16
EP1514482B2 (de) 2016-06-22
EP1955602B1 (de) 2018-04-04
JP2007505078A (ja) 2007-03-08
US8012509B2 (en) 2011-09-06
EP1514482B1 (de) 2008-09-10
AR045745A1 (es) 2005-11-09
WO2005025335A1 (en) 2005-03-24
PT1514482E (pt) 2008-11-19
AU2004271722A1 (en) 2005-03-24
CN1849076A (zh) 2006-10-18
EP1514482A1 (de) 2005-03-16
MXPA06002648A (es) 2006-06-05
AU2004271722B2 (en) 2010-12-16
TW200524545A (en) 2005-08-01

Similar Documents

Publication Publication Date Title
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
ATE468331T1 (de) Neue cyanopyridine-derivate zur behandlung von krebs und anderer erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
EP1572116A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
AU2003231866A8 (en) Herbs and herbal combinations useful for the treatment of microbial infections
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
ATE381347T1 (de) Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
NO20054798D0 (no) Prosessert fettpreparat for forebygging/bedring av livsstils-relaterte sykdommer
DE602005014141D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
EP1773882A4 (de) Diagnose und behandlung von siglec-6-assoziierten krankheiten
DE60323489D1 (de) Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
EP1692305A4 (de) Diagnose und behandlung von krankheiten durch defekte im tuberösen sklerosepfad
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
EP1624786A4 (de) Verfahren zur behandlung und vorbeugung von krankheiten von biologischen kanälen
ATE282604T1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
IL171893A0 (en) Dispersible pharmaceutical composition for treatment of mastitis and otic disorders

Legal Events

Date Code Title Description
8363 Opposition against the patent